ENDRA Life Sciences

ENDRA Life Sciences, Inc. develops medical imaging technology. It operates Thermo-Acoustic Enhanced UltraSound platform to enable clinicians to visualize human tissue composition, function and temperature. The company was founded on July 18, 2007 and is headquartered in Ann Arbor, MI.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

ENDRA Life Sciences reports Q1 loss, eyes market expansion

ENDRA Life Sciences is navigating challenges in a competitive market while leveraging its strengths in innovation and strategic partnerships. The company's performance in Q1 2024 reflects progress in clinical research and regulatory alignment for its TAEUS system.

ENDRA Life Sciences charts strategic course for growth and innovation

ENDRA Life Sciences is making strategic changes to drive future growth and innovation. With a focus on regulatory alignment, clinical trials, and business strategy refinement, the company aims to enhance its market position. Despite financial challenges, ENDRA remains optimistic about its future performance.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

ANN ARBOR, Mich.--(BUSINESS WIRE)---- $NDRA #NAFLD--ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), announces that the Company has raised $8.7 million in gross proceeds year-to-date from the sale of common stock through its at-the-market (ATM) equity facility. Pursuant to its ATM equity offering sales agreement with Ascendiant Capital Markets LLC, the Company sold approximately 20.6 million shares of common stock at an average price of $0.42 per share. “Our AT

ENDRA Life Sciences Raises $8.7 Million in Gross Proceeds Through its At-The-Market Facility

Aterian

Biofrontera

Lyra Therapeutics

Medavail Holdings Inc

We're diving into the top penny stocks for today in our market update for Friday with all the latest news that's moving shares! The post Top Penny Stocks Today: Why ATER, BFRI, NDRA, MDVL and LYRA Stocks Are Soaring Friday appeared first on InvestorPlace.

Top Penny Stocks Today: Why ATER, BFRI, NDRA, MDVL and LYRA Stocks Are Soaring Friday

SeaChange International

Here's what you need to know about trading penny stocks on April 8th The post Trading Penny Stocks on April 8th? What to Know on Friday  appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Trading Penny Stocks on April 8th? What to Know on Friday

ANN ARBOR, Mich.--(BUSINESS WIRE)---- $NDRA #NAFLD--ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), announces receipt of Medical Device Quality Management System ISO 13485:2016 and EN ISO 13485:2016 recertification, under Certificate Number MD 697226 from the British Standards Institution (BSI). This recertification affirms the company's Quality Management System (QMS) meets all current regulatory requirements specific to the medical device industry. The U.S.

ENDRA Life Sciences Achieves Key Quality Management System Certification

ENDRA Life Sciences' (NDRA) CEO Francois Michelon on Q4 2021 Earnings Call Transcript

ANN ARBOR, Mich.--(BUSINESS WIRE)---- $NDRA #NAFLD--ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), today reported financial results for the three months and year ended December 31, 2021 and provided a business update. Highlights of the fourth quarter of 2021 and recent weeks include: Achieved clarity on the U.S. regulatory strategy for the TAEUS system. After extensive and productive dialogue with the U.S. Food and Drug Administration (FDA), ENDRA is now purs

ENDRA Life Sciences Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update

ANN ARBOR, Mich.--(BUSINESS WIRE)---- $NAFLD #NDRA--ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), announces that the Chinese National Intellectual Property Administration has issued ENDRA two new patents, Chinese Patent No. ZL 2019 8 00400927 (the ‘927 patent) titled “Method and System for Determining Fractional Fat Content of Tissue,” and Chinese Patent No. ZL 2019 8 00870250 (the ‘250 patent) titled “Radio Frequency Applicator and Thermoacoustic Imaging Sy

ENDRA Life Sciences Strengthens TAEUS® System Global Intellectual Property Protection with Issuance of 10th and 11th Chinese Patents

ANN ARBOR, Mich.--(BUSINESS WIRE)---- $NDRA #NALFD--ENDRA Life Sciences Inc. (ENDRA) (NASDAQ: NDRA), a pioneer of enhanced ultrasound technologies, today announced that the company will report financial results for the fourth quarter of 2021 on Wednesday, March 30, 2022 after the close of trading on the U.S. financial markets. Management will host a conference call and webcast beginning at 4:30 p.m. Eastern time to discuss the results, provide an update on recent corporate developments and answer questions. Par

ENDRA Life Sciences to Report Fourth Quarter 2021 Financial Results on March 30, 2022

ANN ARBOR, Mich.--(BUSINESS WIRE)---- $NDRA #NAFLD--ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), announces that management will participate in two investor conferences during March: 34th Annual ROTH Conference, March 13-15, 2022 at The Ritz-Carlton Laguna Niguel. Management will be available for one-on-one meetings on Monday, March 14, 2022. In addition, a pre-recorded company presentation will be available in the Investors section of ENDRA's website here.

ENDRA Life Sciences to Participate in Two March Investor Conferences

ANN ARBOR, Mich.--(BUSINESS WIRE)---- $NDRA #NAFLD--ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), announces that the United States Patent and Trademark Office has issued ENDRA a new patent, U.S. Patent No. 11266314 (the ‘314 patent) titled “Method and System for Determining a Material Type of an Object of Interest.” The ‘314 patent protects ENDRA's method and system for determining a material type by utilizing TAEUS. The patent has potential applications bey

ENDRA Life Sciences Strengthens TAEUS® System Intellectual Property with Issuance of 24th U.S. Patent

Phoenix, Arizona--(Newsfile Corp. - February 15, 2022) - The Stock Day Podcast welcomed ENDRA Life Sciences Inc. (NASDAQ: NDRA) ("the Company"), the pioneer of Thermo; Acoustic Enhanced UltraSound (TAEUS®), a ground-breaking technology being developed to visualize tissue like MRI, but at 1/50th the cost and at the point of patient care. CEO of the Company, Francois Michelon, joined Stock Day host Everett Jolly.Jolly began the interview by asking about the Company's decision to focus...

The Stock Day Podcast Hosted ENDRA Life Sciences Inc. to Discuss the Potential of its Thermo Acoustic Enhanced UltraSound (TAEUS(R))

ANN ARBOR, Mich.--(BUSINESS WIRE)---- $NDRA #NAFLD--ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), announces that the European Patent Office (EPO) has issued two new patents to ENDRA, European Patent No. 3668382 (the ‘382 patent) titled “Method and System for Estimating Fractional Fat Content of an Object” and European Patent No. 3661416 (the ‘416 patent) titled “Method for Estimating Fractional Fat Content of an Object.” The ‘382 patent protects ENDRA's meth

ENDRA Life Sciences Strengthens TAEUS® System Global Intellectual Property Portfolio with Issuance of 6th and 7th European Patents

ENDRA Life Sciences Inc plans to voluntarily withdraw its 510(k) application, currently under FDA review for its TAEUS System. Instead, the Company will subsequently submit a De Novo application.

ENDRA Life Voluntarily Withdraws 510(k) Application For Liver Fat Measuring System

ANN ARBOR, Mich.--(BUSINESS WIRE)---- $NAFLD--ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), announced today it will build on the content of its completed 510(k) application and pursue the De Novo pathway for its TAEUS System, which is intended to characterize fatty liver tissue as a means to non-invasively assess and monitor Non-Alcoholic Fatty Liver Disease (NAFLD). ENDRA's updated regulatory strategy is the result of a tremendous amount of productive

ENDRA Life Sciences Provides Update on U.S. Regulatory Strategy for its TAEUS® System

ANN ARBOR, Mich.--(BUSINESS WIRE)---- $NDRA #NAFLD--ENDRA Life Sciences Inc. (ENDRA) (NASDAQ: NDRA), a pioneer of enhanced ultrasound technologies, today announced it has received Institutional Review Board approval from China's renowned Shanghai General Hospital (Shanghai First People's Hospital Affiliated with Shanghai Jiao Tong University), for the first clinical study of ENDRA's Thermo Acoustic Enhanced UltraSound (TAEUS®) device to assess Non-Alcoholic Fatty Liver Disease (NAFLD) in that market. “ENDRA is

ENDRA Life Sciences Expands into China with Shanghai General Hospital Partnership

ANN ARBOR, Mich.--(BUSINESS WIRE)--ENDRA Life Sciences Inc. (ENDRA) (NASDAQ: NDRA), a pioneer of enhanced ultrasound technologies, announces that management will present a company overview at the H.C. Wainwright BioConnect Virtual Conference being held January 10-13, 2022. A webcast of the presentation will be available on-demand beginning January 10, 2022 at 7:00 a.m. Eastern time on the Investors section of ENDRA's website. About ENDRA Life Sciences Inc. ENDRA Life Sciences is the pioneer of

ENDRA Life Sciences to Present at the H.C. Wainwright BioConnect Virtual Conference

Capricor Therapeutics

Boston Beer Company

Sirius XM Holdings Inc

Sunopta

Forget undervalued stocks, there is room for upside even in stocks with rising P/E.

Forget Bargains, Play 5 Stocks With Rising P/E Instead

ANN ARBOR, Mich.--(BUSINESS WIRE)---- $NDRA--ENDRA Life Sciences Inc. (ENDRA) (NASDAQ: NDRA), a pioneer of enhanced ultrasound technologies, today announced that King's College Hospital, London (KCH) is now partnering with ENDRA for a clinical study of ENDRA's Thermo-Acoustic Enhanced Ultrasound (TAEUS®) device for assessing Non-Alcoholic Fatty Liver Disease (NAFLD). “We are thrilled that KCH, a teaching hospital that is world-renowned for pioneering research in liver disease management and transplantati

ENDRA Life Sciences Announces New Clinical Study Partnership with King's College Hospital, London

ANN ARBOR, Mich. & SYDNEY--(BUSINESS WIRE)--ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), and VGI Health Technology Limited (NSX: VTL), a clinical-stage biotechnology company specializing in developing and commercializing evidence-based nutraceuticals and pharmaceuticals, announce today the signing of a collaboration agreement to incorporate ENDRA's proprietary TAEUS technology to support patient screening and biomarker measurement during VG

ENDRA Life Sciences Expands Pharmaceutical Partnerships with VGI Health Technology to Provide TAEUS for Patient Screening and Biomarker Measurement for Phase 2 Study

ANN ARBOR, Mich.--(BUSINESS WIRE)--ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), announces that the United States Patent and Trademark Office has issued two patents, including U.S. Patent No. 11172829 (the ‘829 patent) titled “Thermoacoustic Transducer With Integrated Switch,” and U.S. Patent No. 11176848 (the ‘848 patent) titled “Tissue-mimicking Material for A Multi-modality Imaging Phantom.” The ‘829 patent relates to a novel system for r

ENDRA Life Sciences Further Strengthens TAEUS® System Intellectual Property with Issuance of 22nd and 23rd U.S. Patents

ENDRA Life Sciences' (NDRA) CEO Francois Michelon on Q3 2021 Results - Earnings Call Transcript

ENDRA Life Sciences Inc. (NDRA) delivered earnings and revenue surprises of 14.29% and -100.00%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

ENDRA Life Sciences Inc. (NDRA) Reports Q3 Loss, Misses Revenue Estimates

ANN ARBOR, Mich.--(BUSINESS WIRE)--ENDRA Life Sciences Inc. (ENDRA) (NASDAQ: NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), today reported financial results for the three months ended September 30, 2021 and provided a business update. Highlights of the third quarter of 2021 and recent weeks include: Patient screening was initiated at the University of Pittsburgh Medical Center (UPMC) while it continues to work through a pandemic-related backlog of MRI procedures. Both the UPM

ENDRA Life Sciences Reports Third Quarter 2021 Financial Results and Provides Business Update

ANN ARBOR, Mich.--(BUSINESS WIRE)--ENDRA Life Sciences Inc. (ENDRA) (NASDAQ: NDRA), a pioneer of enhanced ultrasound technologies, today announced that the company will report financial results for the third quarter of 2021 on Monday, November 15, 2021 after the close of trading on the U.S. financial markets. Management will host a conference call and webcast beginning at 4:30 p.m. Eastern time to discuss the results, provide an update on recent corporate developments and answer questions. Part

ENDRA Life Sciences to Report Third Quarter 2021 Financial Results on November 15, 2021

ANN ARBOR, Mich.--(BUSINESS WIRE)--ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), has recently been issued U.S. Patent 11147067 (the ‘067 patent) titled, “Method And System For Monitoring Tissue Temperature” from the United States Patent & Trademark Office. The ‘067 patent relates to a novel method and system for monitoring tissue temperature during surgical procedures using ENDRA's TAEUS® system. ENDRA expects that TAEUS® will be effecti

News for ENDRA Life Sciences Stock (NDRA)